AI Drug Discovery Engine Architecture for Expanded Design Spaces
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug discovery techniques are inefficient, limited in application, and often fail to produce effective therapeutics for certain diseases, particularly due to constrained design spaces and computational inefficiencies, leading to inefficiencies and potential dangers in drug development.
Innovation Solution
An artificial intelligence engine utilizing machine learning models, including generative adversarial networks and causal inference, expands the design space for drug compounds by incorporating various types of drug information and reduces computational complexity, enabling the generation of superior candidate drugs through rational discovery and validation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional drug discovery techniques are used, then the process is simple and familiar, but the design space is constrained and productivity is low
Solution Approach 1:
The AI engine is segmented into distinct functional modules: a creator module for generating candidate drug compounds, a descriptor module for characterizing compounds, and a scientist module for evaluating compounds. This modular architecture enables parallel processing and independent optimization of each function, significantly improving drug discovery productivity while managing system complexity through clear separation of concerns.
Solution Approach 2:
The patent replaces conventional mechanical and empirical drug discovery methods with computational AI systems. Machine learning models and algorithms substitute for traditional laboratory-based screening and design processes, enabling rapid in silico exploration of vast chemical spaces that would be infeasible through conventional experimental approaches alone.
2Adaptability or versatility
If conventional drug discovery techniques are used, then computational resources are limited, but the design space exploration is insufficient
Solution Approach 1:
The creator module performs preliminary generation of candidate drug compounds in silico before experimental validation. By pre-filtering and prioritizing compounds based on predicted properties and activity using AI models, the system expands design space exploration to include millions of virtual compounds while minimizing actual computational and experimental resource consumption on low-priority candidates.
Solution Approach 2:
The AI engine performs excessive action by generating and evaluating far more candidate compounds than would traditionally be tested. The descriptor and scientist modules rapidly assess vast numbers of compounds in silico, allowing the system to explore design spaces far beyond conventional limits and identify promising candidates that would otherwise remain undiscovered.
3Reliability
If conventional drug discovery techniques are used, then the process is straightforward, but the ability to generate effective therapeutics is limited
Solution Approach 1:
The scientist module provides feedback on evaluated compounds back to the creator module, enabling iterative optimization. Performance metrics and evaluation results feed into refined generation processes, allowing the system to learn from previous evaluations and continuously improve therapeutic candidate quality. This closed-loop feedback mechanism enhances reliability by systematically identifying and correcting weaknesses in candidate compounds.
Solution Approach 2:
The AI engine systematically varies and optimizes multiple parameters including molecular structure, chemical properties, and biological activity profiles. By exploring parameter spaces that combine structural information, physicochemical properties, and predicted biological activities, the system generates compounds with optimized therapeutic effectiveness that conventional single-parameter approaches cannot achieve.
Data Source
AI summary
A method is disclosed for using an artificial intelligence engine to generate candidate drug compounds, wherein the method comprises: generating candidate drug compounds comprising sequences via a creator module of the artificial intelligence engine. The method includes generating, via a descriptor module, a respective description for each of the candidate drug compounds at nodes in a knowledge graph, wherein the knowledge graph comprises a multi-dimensional representation of the candidate drug compounds and the respective description comprises drug compound structural information, drug compound activity information, and drug compound semantic information. The method includes determining a shape of the multi-dimensional representation of the candidate drug compounds; determining, based on the shape, a slice configured to be obtained from the representation; determining, using a decoder, which dimensions are included in the slice; and based on the dimensions, determining an effectiveness of a biomedical feature of the slice.